One-carbon Therapeutics recently announced a strategic collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine. The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics expertise to advance molecular insights supporting the clinical development of TH9619.

Through this collaboration, One-carbon Therapeutics will utilize Tempus’ analytical services to characterize the expression landscape across prioritized solid tumor indications. By integrating RNA sequencing data with clinical variables, the teams aim to uncover deep molecular insights that will inform the development of TH9619.

“Understanding the molecular dynamics of one-carbon metabolism across tumor types and treatment settings is fundamental to advancing TH9619 with precision,” said Ana Slipicevic, Chief Executive Officer at One-carbon Therapeutics. “Tempus’ depth of molecular data and analytical rigor enables us to generate statistically robust evidence that can potentially guide clinical decision making and optimize development.”

“At Tempus, our goal is to accelerate progress in oncology by translating complex molecular insights into meaningful therapeutic advances,” said Ezra Cohen, MD, Chief Medical Officer, Oncology, at Tempus. “Through comprehensive analysis of our multimodal dataset, we are supporting One-carbon Therapeutics in characterizing the metabolic signatures across diverse tumor types. These insights are essential to informing research strategies and advancing the development of next-generation targeted cancer therapies.”

By deepening the understanding of the biological mechanisms and genetic profiles associated with one-carbon metabolism across tumor types, the collaboration will strengthen the precision-driven clinical strategy for TH9619. Building on a deep understanding of how cancer cells depend on this pathway, these analyses may help identify patient populations most likely to benefit from treatment. This approach has the potential to enhance development efficiency, reduce uncertainty and ultimately help ensure that innovative targeted therapies reach the patients who need them most.

One-carbon Therapeutics AB is a clinical-stage precision oncology company pioneering novel cancer therapies built on a deep understanding of cancer biology. Its lead program, TH9619 is a first-in-class, potent small-molecule inhibitor of MTHFD1 and MTHFD2, overexpressed enzymes in cancer cells. This inhibition induces toxic folate trapping, starving tumors of the critical DNA building block thymidine, leading to DNA damage and causing cancer cell death. By combining strong mechanistic insight with rigorous clinical development, One-carbon Therapeutics aims to advance potent anti-tumor activity while maintaining improved tolerability for patients with solid tumors.

The company is headquartered in Sweden and is committed to translating cutting-edge science into transformative clinical impact for subjects worldwide. For more information, please visit https://one-carbon.com/

This is a first-in-human, multicenter, open label, dose escalation and expansion study, aiming at evaluating safety, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of TH9619 as monotherapy in subjects with advanced refractory solid tumors, including colorectal cancer, non-small cell lung cancer, head & neck squamous cell carcinoma, gastric cancer or gastroesophageal junction cancer. The trial is currently being conducted across leading academic and clinical research centers in the United Kingdom, France and Spain, with expansion planned across additional European sites in the coming months.

Clinicaltrials.gov NCT07151040; EudraCT No. 2024-519639-40-00

About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.